SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing intense volatility as investors weigh strong international growth and record revenue against concerns over brand momentum and competitive pressures ahead of its upcoming earnings report. The community is actively debating whether the recent share price slide near 52-week lows represents a deliberate institutional accumulation phase or a signal of fundamental weakness.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and intense community debate as investors weigh strong financial results and aggressive growth targets against concerns over potential share offerings and broader software sector weakness. While many remain bullish on the company's AI-driven ad engine and cash flow, traders are actively discussing the stock's unpredictable price swings and high-stakes positioning ahead of upcoming catalyst events.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing significant volatility and a sharp price correction as the market weighs competitive pressures from new AI agent technologies against the company's long-term infrastructure potential. Investors are actively debating whether this pullback represents a major fundamental breakdown or an overreaction that offers a strategic buying opportunity for the edge computing leader.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant leadership overhaul that replaced the former CEO with Chairman Kevin Tang, sparking optimism for a potential buyout. The community is actively debating the strategic implications of Tangs aggressive management style and the company's recent acquisition of Kezar Life Sciences as key catalysts for future value creation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors react to a significant data center campus development in Thailand and an expanded partnership with Yotta, fueling speculation about long-term revenue potential and a possible short squeeze due to high short interest and a limited tradable float. The community is actively debating the legitimacy of these massive contract announcements and the company's ability to finance them, with many longs expressing high conviction in the stock's future as it attempts to break through key technical resistance levels.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is currently trending following a report identifying the company as a key stealth supplier for Nvidia and Apple's advanced optical infrastructure, specifically regarding wafer-level optics for Co-Packaged Optics. The community is actively debating the sustainability of this price action, with some investors pointing to long-term growth in AI data center components, while skeptics caution against potential volatility and speculative hype.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is heading into earnings with heightened volatility as investors weigh the company's path to profitability and potential AI-driven ad performance against concerns over executive leadership and stagnant North American user growth. While the community is divided between those betting on a turnaround through cost-cutting and potential buyout interest, others are actively preparing for typical post-earnings swings, debating if the stock is a deep-value opportunity or a long-term trap.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility as investors weigh strong fundamental performance and profitability against intense short-interest and broader macro uncertainty. While the community is actively discussing the stock's potential for a massive re-rating driven by its AI underwriting model and recent institutional wins, the price action remains heavily influenced by speculative trading and regional geopolitical concerns affecting the broader fintech sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors weigh strong demand for its high-energy silicon anode battery technology against ongoing volatility driven by warrant redemption mechanics. Community discussion is focused on the company's expanding order backlog in the defense and electric mobility sectors, with many traders closely monitoring whether the share price can maintain the critical support levels required to trigger warrant exercises.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following the sale of its SDX portfolio for $50 million and the full repayment of its $63 million term loan, moves that have significantly de-risked the balance sheet and eliminated long-standing litigation overhang. Investors are actively discussing whether this financial cleanup serves as a strategic precursor to an imminent buyout, while others remain focused on upcoming catalysts like European regulatory approval and patent extensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday

Capricor Therapeutics (NASDAQ:CAPR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at...

Oppenheimer & Co. Inc. Cuts Stock Holdings in Capricor Therapeutics, Inc. $CAPR

Oppenheimer & Co. Inc. trimmed its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 40.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,813 shares of the biotechnology company's stock after selling 54,600 s...

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.1% - Still a Buy?

Capricor Therapeutics (NASDAQ:CAPR) Trading 7.1% Higher - What's Next...

<ul class="summary-bullets"><li>Hemmati is reportedly being considered for a leadership role at the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research.</li><li>The regulatory spotlight has intensified following recent FDA moves, including the fast-tracked expanded access for Revolution Medicines’ cancer drug, Daraxonrasib.</li><li>Capricor awaits an FDA decision on Deramiocel by Aug. 22.</li></ul>Shares of Capricor Therapeutics, Inc. (CAPR) drew retail attention on Monday after a former executive, eyeing a potential FDA chief role, said drug approval should only be viewed as a “building permit” rather than a sign that a therapy is the top choice.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> declined 8% on Friday as investors tracked regulatory developments ahead of a high-stakes decision on its Duchenne muscular dystrophy (DMD) therapy, Deramiocel.The focus increased after Houman David Hemmati, who previously served at the company and is now being considered for a leadership role at the U.S. Food and Drug Administration (FDA).<h2 class="st-heading-2">Hemmati: Approval Is Just A Safety Check&nbsp;</h2>Hemmati&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/houmanhemmati/status/2051104165112303924">said on X</a> that FDA approval does not indicate that a drug is “incredible” or the best option available, but simply confirms it meets established standards for safety and efficacy. “It’s like a building permit: it simply confirms the therapy meets rigorous standards for safety and efficacy,” he said.He said that patients can choose not to take a drug, doctors may decide not to prescribe it, and insurers may opt not to cover it if it is not appropriate, stressing that approval is only one part of a broader framework for real-world use.“Taking away choice because a drug isn’t “absolutely perfect” means patients and physicians never even get the option to consider it. Putting patients first means preserving every possible tool—so families and doctors can decide together,” Hemmati said.&nbsp;<h2 class="st-heading-2">Hemmati Emerges As FDA Role Contender&nbsp;</h2>Hemmati, who served as vice president of medical and clinical development at Capricor between 2015 and 2017, is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-ex-capricor-exec-fda-role-ahead-of-dmd-decision/cZJpyVMRIHI">reportedly</a> among candidates being considered to lead the FDA’s Center for Biologics Evaluation and Research, which oversees gene and cell therapy approvals.The potential leadership change follows the departure of CBER director Vinay Prasad, whose tenure drew criticism from the biotech sector over decisions affecting rare-disease therapies.Recent regulatory decisions have also drawn focus to the agency’s approach. The FDA last week granted a “safe to proceed” letter to Revolution Medicines for expanded access to its pancreatic cancer drug Daraxonrasib, allowing treatment for patients with previously treated metastatic disease.The agency cleared the request within two days of submission, with Commissioner Marty Makary saying that the move is a commitment to facilitate early access to therapies for serious and life-threatening conditions. Daraxonrasib, a RAS inhibitor, has received Breakthrough Therapy and Orphan Drug designations and is expected to be submitted for approval under the agency’s National Priority Voucher program.<h2 class="st-heading-2">CAPR Awaits High-Stakes DMD Decision</h2>The developments come as Capricor awaits an FDA decision on Deramiocel, expected by Aug. 22. The therapy targets DMD, a genetic condition that causes progressive muscle weakness in children.The FDA resumed its review in March after issuing a Complete Response Letter in July 2025 requesting additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing a 54% slowing in upper-limb function decline and a 91% reduction in cardiac disease progression compared with placebo. Deramiocel consists of donor-derived cardiac cells to reduce inflammation from muscle degeneration in DMD.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR was ‘bullish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_31e2b2ea6c.webp" alt="capr ss.png" width="970" height="143"><figcaption>CAPR sentiment and message volume as of May 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PortfolioAutopsy/message/652143880">called</a> CAPR a “Clinical-stage biotech with high risk and potential reward tied to trial success”<stembedurl>https://stocktwits.com/PortfolioAutopsy/message/652143880</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Stonksgoingup/message/652124339">said</a>, “4 months max until we can finally start selling and get treatment for these boys. Time really flies since our end of feb submission”<stembedurl>https://stocktwits.com/Stonksgoingup/message/652124339</stembedurl>CAPR stock has surged 143% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-jumps-ev-maker-brings-back-original-software-chief/cZQMhiXRe7Z">Nio Stock Jumps Overnight: EV Maker Brings Back Original Chief To Run Software Behind Its Cars&nbsp;</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals

Former Capricor executive Houman David Hemmati said FDA approval should be viewed as a “building permit,” not proof a drug is the best option.

Equity

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%  - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5% - Should You Sell...

Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR

Moody Aldrich Partners LLC purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 208,755 shares of the biotechnology compan...

<ul><li>The company’s management highlighted that video-based assessments of everyday tasks showed that Deramiocel helped slow disease progression.</li><li>The U.S. FDA is expected to announce its decision on Deramiocel on August 22.</li><li>According to a Bloomberg report, a former Capricor executive is being considered for a key leadership role at the FDA’s Center for Biologics Evaluation and Research.</li></ul>Capricor Therapeutics (CAPR) drew investor attention on Wednesday, after the biotech firm presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne Muscular Dystrophy (DMD) at the American Academy of Neurology 2026 Annual Meeting in Chicago.<a href="https://stocktwits.com/symbol/CAPR">CAPR shares</a> gave up early gains, trading 1% lower.<h2>FDA Decision Expected In August</h2>Capricor’s Biologics License Application (BLA) for the treatment is currently under review by the U.S. Food and Drug Administration (FDA), with a decision expected by Aug. 22, 2026.The U.S. Food and Drug Administration resumed its review of Deramiocel in March after previously issuing a Complete Response Letter in July 2025, indicating the therapy needed additional data for approval. Capricor resubmitted its application with updated Phase 3 HOPE-3 results, which showed a 54% slower decline in upper-limb function and a 91% reduction in cardiac disease progression compared to placebo.Further supporting the findings, cardiac MRI data showed a significant reduction in heart scarring in patients treated with Deramiocel after 12 months. The therapy is designed to reduce inflammation linked to muscle damage in DMD.<h2>Treatment Highlights Patients’ Ability To Feed Themselves</h2>The firm’s management highlighted that video-based assessments of everyday tasks also showed that Deramiocel helped slow disease progression, especially in patients’ ability to feed themselves.“No therapeutic has ever delivered a statistically and clinically meaningful difference in the upper limb functional primary endpoint of Performance of the Upper Limb (PUL v2.0),” said Aravindhan Veerapandiyan, Associate Professor and Director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital.“These findings were further supported by an alternative measure of upper limb function, specifically video recordings of tasks performed at home, which showed meaningful slowing of disease progression in the ability to self-feed, a function central to patient independence.”Meanwhile, retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.<h2>Hemmati’s Potential FDA Appointment Sparks Retail Buzz</h2>A former Capricor executive is being considered for a key leadership role at the U.S. Food and Drug Administration, according to a Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">report</a> last week.Houman Hemmati is among the candidates being interviewed by FDA Commissioner Marty Makary to lead the Center for Biologics Evaluation and Research (CBER), the division responsible for reviewing vaccines and advanced gene and cell therapies, including treatments for rare diseases like Duchenne muscular dystrophy.However, no final decision has been made yet, and the agency is still reviewing potential candidates.One user expects the stock to pop on the confirmation of the news.<stembedurl>https://stocktwits.com/haha1978/message/650933730</stembedurl>The leadership vacancy at the CBER follows the departure of Vinay Prasad, whose tenure drew criticism from parts of the biotech industry over regulatory decisions on rare-disease treatments.The stock has gained more than 17% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy

The biotech firm presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne Muscular Dystrophy at the American Academy of Neurology 2026 Annual Meeting in Chicago.

Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6%

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 9,878,573 shares, a growth...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, MarketBeat...

<ul class="summary-bullets"><li>Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017.</li><li>Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected by Aug. 22.</li><li>The FDA resumed review last month after issuing a Complete Response Letter in July 2025, requesting additional clinical data.</li></ul>Shares of Capricor Therapeutics (CAPR) jumped 1% in premarket trading on Tuesday after reports said a former company executive is being considered to lead the FDA’s top gene therapy division just months before a key approval decision on its Duchenne muscular dystrophy (DMD) treatment.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped 11% on Monday to end at $34.54, logging its best session in nearly two months.<h2 class="st-heading-2">Former Capricor Executive Emerges As FDA Biologics Chief Candidate</h2>Houman Hemmati, who served as vice president of medical and clinical development for new therapies at Capricor between 2015 and 2017, is among the candidates being interviewed by FDA Commissioner Marty Makary to head the Center for Biologics Evaluation and Research, or CBER, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">reported</a>.The division oversees approvals of vaccines and advanced gene and cell therapies, including treatments for rare diseases such as DMD. However, HHS spokesperson Andrew Nixon reportedly said no selection has been finalized and that the agency is still evaluating candidates.<h2 class="st-heading-2">CAPR Awaits Key FDA Ruling On DMD Therapy</h2>The development comes as Capricor awaits an FDA decision on Deramiocel, its investigational therapy for DMD, a rare genetic condition that causes progressive muscle weakness in children, expected by Aug. 22.The FDA resumed review of Deramiocel last month after issuing a Complete Response Letter (CRL) in July 2025, which indicated earlier that the agency could not approve the drug in its current form and typically requests additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing 54% slower deterioration in upper-limb function and 91% slowing of cardiac disease progression, both statistically significant compared with placebo.Deramiocel consists of donor-derived cardiac cells, which reduces inflammation linked to muscle degeneration in DMD.<h2 class="st-heading-2">Prasad Exit Seen As Positive For Biotech Approvals</h2>The CBER leadership opening follows the departure this month of outgoing director Vinay Prasad, whose tenure drew criticism from the biotech industry over regulatory decisions affecting rare-disease therapies.Prasad’s exit news lifted several biotech stocks last month, with BMO Capital Markets calling the change “a sigh of relief” for the sector and saying it could improve approval prospects for multiple companies developing advanced therapies.During his tenure, Prasad was involved in disputes with companies, including Sarepta Therapeutics, over gene-therapy reviews and disagreements with UniQure and Regenxbio. He also briefly stepped away from the agency last year amid political criticism over regulatory decisions before returning weeks later with Makary’s support.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR jumped to ‘bullish’ from ‘bearish’ levels over the past day amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_26c2d1b5ac.webp" alt="capr ss.png" width="963" height="149"><figcaption>CAPR sentiment and message volume as of April 14 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/graywolf/message/650157552">said</a>, “$45-50 is my guess if the appointment is confirmed. 75+ upon approval, and $100+ with sale numbers,” referring to the prospects of Hemmati leading the CBER.<stembedurl>https://stocktwits.com/graywolf/message/650157552</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/WBinthehouse/message/650152118">said</a>, “if Dr Hemmati gets appointed as CBER chief, Vinay Prasad is gonna want credit for CAPRs approval. Will beat David to the punch. Guaranteed! Lol”<stembedurl>https://stocktwits.com/WBinthehouse/message/650152118</stembedurl>CAPR stock has jumped over 270% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-killers-musk-taunts-rivals-after-q1-us-deliveries-top-ev-market/cZJpx1BRIHE">'What Happened To All The Tesla Killers?' Elon Musk Taunts Rivals As Q1 US Deliveries Beat Every Other EV Maker Combined</a>

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision

Outgoing CBER director Vinay Prasad will depart this month, boosting approval prospects for several rare-disease therapies.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.53	--	--	N/A
Q4 '25	-$0.51	-$0.62	-21.81%	MISSED
Q3 '25	-$0.55	-$0.54	1.22%	BEAT
Q2 '25	-$0.48	-$0.57	-19.75%	MISSED
Q1 '25	-$0.32	-$0.53	-67.37%	MISSED

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CAPR News

CAPRCapricor Therapeutics Inc